Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIPAN trial of octreotide for HHT-related gastrointestinal bleeding
NL-OMON46190Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hereditary hemorrhagic telangiectasia (HHT) comparing Octreotide treatment with Observation/control (2 arms). Primary endpoint: Successful response. Started Dec 2019; status: completed.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON46190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46190.